Dr. Khanani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
950 Ryland St
Reno, NV 89502Phone+1 775-329-0286Fax+1 775-329-4243
Education & Training
Texas Tech University Health Sciences Center at LubbockResidency, Ophthalmology, 2005 - 2008
Baylor College of MedicineInternship, Internal Medicine, 2004 - 2005- Texas Tech University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
NV State Medical License 2010 - 2025
TX State Medical License 2007 - 2012- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
- A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Start of enrollment: 2014 Aug 01
- Cooling Anesthesia for Intravitreal Injection Start of enrollment: 2018 Nov 30
- Join now to see all
Publications & Presentations
PubMed
- Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.Aamir A Aziz, Arshad M Khanani, Hannah Khan, Eileen Lauer, Ibrahim Khanani
Eye. 2024-12-11 - Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.Arshad M Khanani, Aamir A Aziz, Zoha A Khanani, Hannah Khan, Ohidul Mojumder
American Journal of Ophthalmology. 2024-12-07 - Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.Melissa A Calton, Roxanne H Croze, Christian Burns, Ghezal Beliakoff, Tandis Vazin
Investigative Ophthalmology & Visual Science. 2024-12-02
Journal Articles
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Press Mentions
Extended Dosing Intervals Possible with Aflibercept in Diabetic Macular EdemaNovember 18th, 2024- Dry Age-Related Macular Degeneration Highlights from ASRS 2024November 12th, 2024
- New Framework for Deciding When to Operate on Patients with Epiretinal MembranesNovember 11th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
